Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type I receptor in rats

This article was published in the following Dove Press journal:
Drug Design, Development and Therapy

Rong-Hua Zheng^{1,2}

Xiao-Jie Bai¹

Wei-Wei Zhang¹

Jing Wang¹

Feng Bai¹

Cai-Ping Yan¹

Erskine A James³

Himangshu S Bose⁴

Ning-Ping Wang^{1,4}

Zhi-Qing Zhao^{1,4}

¹Department of Physiology, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China; ²Department of Medicine, Linfen Vocational and Technical College, Linfen, Shanxi, People's Republic of China; ³Department of Internal Medicine, Navicent Health, Macon, GA, USA; ⁴Basic Biomedical Sciences, Mercer University School of Medicine, Savannah, GA, USA

Objective: Angiotensin II (Ang II) is known to contribute to the pathogenesis of heart failure by eliciting cardiac remodeling and dysfunction. The glucagon-like peptide-1 (GLP-1) has been shown to exert cardioprotective effects in animals and patients. This study investigates whether GLP-1 receptor agonist liraglutide inhibits abdominal aortic constriction (AAC)-induced cardiac fibrosis and dysfunction through blocking Ang II type I receptor (AT1R) signaling.

Methods: Sprague-Dawley rats were subjected to sham operation and abdominal aortic banding procedure for 16 weeks. In treated rats, liraglutide (0.3 mg/kg) was subcutaneously injected twice daily or telmisartan (10 mg/kg/day), the AT1R blocker, was administered by gastric gavage.

Results: Relative to the animals with AAC, liraglutide reduced protein level of the AT1R and upregulated the AT2R, as evidenced by reduced ratio of AT1R/AT2R (0.59 ± 0.04 vs. 0.91 ± 0.06 , $p < 0.05$). Furthermore, the expression of angiotensin converting enzyme 2 was upregulated, tissue levels of malondialdehyde and B-type natriuretic peptide were reduced, and superoxide dismutase activity was increased. Along with a reduction in HW/BW ratio, cardiomyocyte hypertrophy was inhibited. In coincidence with these changes, liraglutide significantly decreased the populations of macrophages and myofibroblasts in the myocardium, which were accompanied by reduced protein levels of transforming growth factor $\beta 1$, Smad2/3/4, and upregulated smad7. The synthesis of collagen I and III was inhibited and collagen-rich fibrosis was attenuated. Consistent with these findings, cardiac systolic function was preserved, as shown by increased left ventricular systolic pressure (110 ± 5 vs. 99 ± 2 mmHg, $p < 0.05$), ejection fraction ($83\% \pm 2\%$ vs. $69\% \pm 4\%$, $p < 0.05$) and fraction shortening ($49\% \pm 2\%$ vs. $35\% \pm 3\%$, $p < 0.05$). Treatment with telmisartan provided a comparable level of protection as compared with liraglutide in all the parameters measured.

Conclusion: Taken together, liraglutide ameliorates cardiac fibrosis and dysfunction, potentially via suppressing the AT1R-mediated events. These data indicate that liraglutide might be selected as an add-on drug to prevent the progression of heart failure.

Keywords: angiotensin II AT1 receptor, cardiac fibrosis, cardiac function, liraglutide, telmisartan

Correspondence: Zhi-Qing Zhao
Basic Biomedical Sciences, Mercer
University School of Medicine, 1250 East
66th Street, Savannah, GA 31404, USA
Tel +86 912 721 8208
Fax +86 912 721 8268
Email zhao_z@mercer.edu

Introduction

Maladaptive cardiac remodeling referring to molecular, cellular and interstitial alterations in the myocardium, is characterized by histopathological changes in

the structure, shape, and function of the heart, and often leads to the development of heart failure.^{1–3} Animal studies and clinical observations have shown that cardiac remodeling exhibits progressive worsening of cardiac dysfunction with a higher risk of cardiovascular morbidity and mortality.^{4–6} Tissue fibrosis as a key component of cardiac remodeling occurs inevitably in the chronic phases of the different pathological conditions, including hypertension, myocardial infarction, inflammation, and hypertrophic cardiomyopathy.^{6,7}

Angiotensin II (Ang II), the major bioactive peptide product of the renin-angiotensin-aldosterone system, plays an important pathophysiological role in the cardiovascular system, including blood pressure regulation, systemic inflammatory response, interstitial collagen deposition, and tissue fibrotic formation through its interaction with the type 1 receptor (AT1R).^{8,9} The inhibition of Ang II formation or the blockade of the AT1R activation with Ang II-converting enzyme inhibitors (ACEi) or AT1 receptor blocker (ARBs) has emerged as an appealing therapeutic approach to prevent cardiac dysfunction and heart failure by attenuating progression of cardiac remodeling.^{10,11} Our laboratory has had a longstanding interest in the areas of Ang II-induced cardiomyocyte hypertrophy, tissue fibrosis, and cardiac dysfunction. We have previously reported that pharmacological inhibition of the AT1R significantly reduces cardiac fibrosis and improves cardiac function.^{12,13} Although ACEi or ARBs have achieved good clinical results, according to the reports of recent years, there might be substantial side effects such as cough, angioedema, and hypotension.^{14,15} Therefore, adjunctive therapies to reduce cardiac remodeling and promote cardiac recovery through modulating the Ang II system still merits further investigation.

Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone produced in the intestinal endocrine L-cells, and plays an important role in glucose homeostasis to control food intake. Plasma half-life of endogenous GLP-1 is short, and can be rapidly degraded by the enzyme dipeptidyl peptidase-4.¹⁶ Liraglutide is a long-acting GLP-1 receptor agonist, and has been widely used in the treatment of type 2 diabetes mellitus.¹⁷ Recently, extensive research studies have shown that liraglutide not only possesses the glucose-dependent hypoglycemic effects, but also exerts the protection in variety of cardiovascular diseases independent of the mechanism of blood sugar regulation, such as preservation in vascular endothelial cell function, regulation in blood pressure, attenuation in cardiomyocyte

injury, and improvement in heart function.^{18–20} Our laboratory has previously reported that liraglutide protects the heart against Ang II infusion-induced cardiac fibrosis via inhibiting the AT1R-activated signaling.^{12,13,21} However, it is unknown whether liraglutide attenuates the pressure overload-induced heart failure. In the present study, we selected a rat model of transverse abdominal aortic constriction (AAC) to demonstrate the potential beneficial effects of liraglutide on cardiac fibrosis and heart function underlying mechanisms through modulating adverse actions of Ang II, including expression of the AT1R, activation of oxidative stress, migration of macrophages, proliferation of myofibroblasts, and deposition of collagens. To further support whether liraglutide exerted effects are mediated by blocking activation of the AT1R signaling, telmisartan, the AT1R antagonist, was selected for comparison. Cardiomyocyte hypertrophy and myocardial interstitial fibrosis were defined by morphological staining, and heart contractile function was assessed using two-dimensional echocardiography.

Materials and methods

Animals and AAC model

Male Sprague-Dawley rats weighting 200–250 g from 6 to 8 weeks were obtained from the Animal Laboratory Center of Shanxi Medical University, Taiyuan, People's Republic of China. The procedures were in compliance with “The Guide for the Care of Use of Laboratory Animals” published by the US National Institute of Health (8th edition, revised, 2011). The experimental protocol was approved by the Experimental Animal Management Committee of Shanxi Medical University. Rats were housed under normal conditions (a 12 hrs light/dark cycle, temperature at 20–25°C, and relative humidity at 50–60%).

The rats were placed in a supine position on a surgery platform and an incision was made along the manubrium and midline of the abdomen. After the abdominal cavity was opened, the abdominal aorta was ligated using a 4–0 silk suture with a 7-gauge needle that is placed parallel to the aortic arch at a point of 1 cm above the left renal artery. The degree of AAC was controlled by withdrawing the needle under the suture. After the operation was completed, the penicillin was injected and animals were allowed to recover for 1 week before signing the experimental groups.

Experimental group and study protocol

The rats were randomly divided into four groups ($n=6$ in each group) after surgery: 1) Sham control: rats underwent the same surgical procedure without banding the aorta; 2) AAC: rats were subjected to AAC for 16 weeks; 3) liraglutide treatment: rats were received a subcutaneous injection of liraglutide (Novo Nordisk Pharma Ltd., Glaxo, Denmark) at a dose of 0.3 mg/kg twice daily after AAC; 4) telmisartan treatment: rats were administered telmisartan (Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA) via gastric gavage at a dose of 10 mg/kg/day after AAC. The doses selected for liraglutide and telmisartan were based on previous experiments.^{12,21}

Measurement of the body weight and blood glucose

Rat body weight and blood glucose value were measured every 2 weeks. The rats were fasted overnight (14–17 hrs) before the blood glucose was measured. The blood was collected from the tail vein of the rats on the next day, and the level of blood glucose was measured with blood glucose test paper (Glucometer, Blood sugar paper, Johnson, USA).

Measurement of the lipid peroxidation level, antioxidant enzyme activity, N terminal pro B type natriuretic peptide

The hearts were homogenized in phosphate buffer. The level of malonaldehyde (MDA) in the left ventricle was measured as the index of lipid peroxidation with an MDA detection kit (Jiancheng Bioengineering Institute, Nanjing, People's Republic of China). Superoxide dismutase (SOD) activity to represent the ability of trapping oxygen radicals was determined with a SOD detection kit (Jiancheng Bioengineering Institute). N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) level in response to pressure overload were determined using a detection kit (Xitang Bioengineering Institute, Shanghai, China).

Determination of heart/body weight (HW/BW) ratio and myocyte sectional area (MSA)

At the end of the experiment, the rat heart was rapidly removed and cleaned in the ice saline. After drying, the heart/body weight (HW/BW) index was calculated as heart weight divided by body weight (mg/g tissue). The left

ventricle was then divided into two parts: one part was frozen immediately in the liquid nitrogen and the other part was paraffin-embedded. The MSA of cardiomyocytes was measured after conventional HE staining. Six areas in a high-powered field were randomly selected from each tissue section with a digital camera through 20X objective lens under light microscopy. Thirty cardiomyocytes as having a visible nucleus and intact cellular membrane were selected for the measurement and analysis using image analysis software (Image J; NIH, Rockville, MD, USA).

Expression of AT1R, AT2R, TGF- β 1, Smads, and collagens by Western blot assay

The protein contents of the AT1R and AT2R, TGF- β 1, Smads, and collagens were determined by Western blot assay.^{12,21} In brief, the heart tissue samples from different groups were homogenized in a lysis buffer and the protein concentration was measured by the BCA Protein Assay reagent kit (Boster Biotech, Wuhan, People's Republic of China). The protein was then boiled and loaded onto SDS-PAGE to perform an electrophoresis. The protein was then transferred from the gel to the nitrocellulose membrane. Membranes were subsequently exposed to one of the following antibodies: the rabbit anti-AT1 and AT2 receptor polyclonal antibodies (Santa Cruz Biotechnology Inc., Dallas, TX, USA), a mouse anti-TGF- β 1 monoclonal antibody (Abcam, Inc. MA, USA), the rabbit anti-p-Smad2, p-Smad3, anti-Smad2, Smad3, Smad4 and Smad7 monoclonal antibodies (Cell Signaling Technology, MA, USA), the mouse anti-collagen type I and III monoclonal antibodies (Abcam). Appropriate secondary antibodies were used, and the antibody-antigen complexes in all membranes were detected by the ECL PLUS kit (Boster Biotech). Subsequently, the protein bands exposed by the UVP gel imaging system (UVP, MA, USA) were analyzed by gray value using image J software, and the protein gray value of β -actin was used as an internal parameter for protein loading control.

Immunohistochemical staining for ACE2, macrophages, myofibroblasts, and TGF- β 1

The heart samples were cut into 4 μ m thickness and immunohistochemical staining was performed to identify the expression of the ACE2, macrophages, myofibroblasts, and TGF- β 1 in the myocardium as we reported previously.^{12,21} In brief, the tissue sections were deparaffinized in xylene, dehydrated in graded ethanol and stained using a rabbit polyclonal antibody

against ACE2 (Abcam), a rabbit monoclonal antibody against macrophages (CD68; EMD Millipore, Billerica, MA, USA), a monoclonal antibody against alpha-smooth muscle actin (α -SMA, Abcam), and a mouse anti-TGF- β 1 monoclonal antibody (Abcam), respectively. Bound antibodies were detected by horseradish peroxidase-conjugated corresponding IgG, and diaminobenzidine tetrahydrochloride was used to observe the presence and location of ACE2, macrophages, myofibroblasts, and TGF- β 1. Five sections from the different animals in each group were selected for an image acquisition using Aperio Digital pathological scanning system (Vista, CA, USA). The mean optical density (MOD) in the expression of ACE2, TGF- β 1, and the number of macrophages and myofibroblasts per high-powered field were determined using cytoplasmic v2 software (Vista).

Detection of tissue fibrosis by Masson's trichrome staining

Masson's trichrome staining was used to evaluate the interstitial collagen deposition in the myocardium and quantitatively analyzed by morphometry as previously reported.^{12,21} In brief, the tissue samples were sectioned to a thickness of 6 μ m using a Microtome (Leica RM2135, Meyer Instruments, TX, USA). Six randomly selected high-powered fields per section were selected to determine the areas of positively stained collagen (ImageJ, NIH, MA, USA). The staining pattern by Masson's trichrome turns collagen blue, nuclei black, and viable muscle fiber as red.

Evaluation of global cardiac function by echocardiography and hemodynamic analysis

At the end of the observation period, the rats were anesthetized with inhaled 1.5% isoflurane, and transthoracic echocardiography was performed using a 15s MHz linear transducer. Percent fraction shortening, ejection fraction (EF), and left ventricular internal dimension (LVIDd) were calculated using a two-dimensional guided M-mode ultrasound system (Vivid 7, GE Healthcare, Waukesha, WI, USA).¹³ Over three consecutive cardiac cycles were averaged for measurements. For hemodynamic analysis, both the carotid arteries were cannulated with a polyethylene catheter connected to a Statham transducer to measure the mean carotid pressure via a BL-410 biological signal acquisition and processing system (Techman Software Co., Ltd., Chengdu, China). The polyethylene catheter within the right carotid artery was then inserted into the left

ventricle to determine the cardiac performance, including heart rate, left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), and maximum positive ($+dp/dt_{max}$)/negative ($-dp/dt_{max}$) values of the first derivative of left ventricular pressure.¹³

Statistical analysis

All data were showed as the mean $\pm$ standard error using Prism v 7.01 analysis system (GraphPad Software Inc, La Jolla, CA, USA). A one-way ANOVA followed by Student–Newman–Keul's post hoc test was used to analyze group differences in the band intensity of AT1R, AT2R, TGF- β 1, Smads, the MOD in the expression of ACE2, TGF- β 1, collagens, the number of macrophages and myofibroblasts accumulated in the myocardium. The value of $p < 0.05$ was accepted as a statistical significance.

Results

Effects of liraglutide and telmisartan on blood sugar, oxidative stress, antioxidant enzyme, cardiac hypertrophy, and HW/BW ratio after AAC

The body weight and blood sugar were monitored every 2 weeks starting from the second week of the observation. As shown in Figure 1A, no statistically significant difference in these two parameters was found between the Sham and AAC groups. Treatment with liraglutide and telmisartan also did not alter the body weight and blood sugar during the course of the experiment.

The content of MDA and the activity of SOD in the heart were used to estimate the levels of lipid peroxidation and tissue antioxidant ability. As shown in Figure 1B, AAC significantly increased MDA (23.4 ± 1.3 vs 16.3 ± 0.6 nmol/mg, $p < 0.05$) and reduced SOD (8.1 ± 0.8 vs 10.4 ± 0.4 U/mg, $p < 0.05$) compared with the Sham group, suggesting that chronic pressure overload increases cardiac oxidative status. Relative to the AAC group, administration of liraglutide or telmisartan reduced MDA level to 15.9 ± 1.6 and 17.2 ± 1.4 nmol/mg (all $p < 0.05$ vs AAC group), respectively, and increased SOD enzyme activity by 11.9 ± 1.2 and 11.6 ± 1.1 U/mg, all $p < 0.05$ vs AAC group, respectively, implying improved antioxidant ability of the heart.

The measurement of NT-pro-BNP levels were used to estimate the degree of heart failure and the calculation of MSA and HW/BW ratio was selected to evaluate cardiac hypertrophy. As shown in Figure 1C, AAC significantly increased NT-pro-BNP level at 16 weeks

Figure 1 Effects of liraglutide and telmisartan on body weight, blood sugar, MDA, SOD, NT-pro-BNP, and cardiac hypertrophy after abdominal aortic constriction (AAC). (A) body weight and blood glucose were measured among different groups. (B and C) Levels of MDA, SOD, and NT-pro-BNP activity in myocardial tissue were determined using Elisa kits. (D) MSA in series was measured morphometrically at a HPF (original magnification: 200; scale bars: 100 μm). (E) Heart/body weight ratio (HW/BW, mg/g) was calculated by weight. Values are mean $\pm$ SEM (n=6/group). * $p<0.05$ AAC vs Sham; # $p<0.05$ liraglutide (Lira) or telmisartan (Telmi) vs AAC.

Abbreviations: MDA, malonaldehyde; SOD, superoxide dismutase; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; MSA, myocyte sectional area.

of observation relative to the Sham animals, which were reduced by liraglutide (14.8 ± 1.3 pg/mL) and telmisartan (10.3 ± 0.8 pg/mL) compared with AAC group (48.4 ± 8.6 pg/mL), respectively, all $p<0.05$. Consistent with this change, the MSA in the AAC group increased significantly relative to the Sham group (1512 ± 99 vs 586 ± 98 μm^2 , $p<0.05$). Treatment with liraglutide or telmisartan comparatively reduced the MSA to 766 ± 61 μm^2 or 871 ± 51 μm^2 (all $p<0.05$ vs AAC group, Figure 1D). The inhibitory effect of liraglutide or telmisartan on cardiac hypertrophy was further confirmed by the HW/BW ratio (Figure 1E). Relative to the Sham

group, AAC group significantly increased the HW/BW ratio relative to the Sham group (3.38 ± 0.17 vs 2.46 ± 0.05 , $p<0.05$), which was significantly reduced by liraglutide or telmisartan (2.63 ± 0.09 and 2.77 ± 0.05 vs AAC group, all $p<0.05$).

Effects of liraglutide and telmisartan on expression of AT1R, AT2R, AT1R/AT2R ratio, and ACE2 after AAC

The expression of Ang II receptors was detected using Western blot assay. At the end of 16 weeks of AAC,

Figure 2 Effects of liraglutide and telmisartan on the expression of AT1R, AT2R, AT1R/AT2R ratio, and ACE2 after AAC. (A and B) Protein levels of AT1R and AT2R were detected by Western blot assay. (C) AT1R/AT2R ratio was calculated from the intensity of each individual bands. (D) ACE2 expression in the intermyocardium and intracardiac vessels was determined using immunohistochemical staining and calculated as mean optical density (MOD) in the tissue section (magnification: 200; scale bars: 100 μ m). Values are mean $\pm$ SEM (n=6/group). * p <0.05 AAC vs Sham; # p <0.05 Lira or Telmi vs AAC.

Abbreviation: AAC, abdominal aortic constriction.

relative to the Sham control, the protein level of the AT1R was significantly increased by $10.55 \pm 2.5\%$ (Figure 2A), and the protein expression of the AT2R was decreased by $36.43 \pm 5.6\%$ (Figure 2B), all p <0.05, whereas the expression patterns of AT1R and AT2R in the liraglutide and the telmisartan groups were reversed, as evidenced by a reduced AT1R/AT2R ratio (Figure 2C). Immunohistochemical staining showed that the expression of ACE2 in the perivascular and interstitial myocardium is significantly attenuated in the AAC group relative to the Sham group (Figure 2D). Relative to the AAC group, administration of liraglutide or telmisartan preserved the expression of ACE2 at week 16.

Effects of liraglutide and telmisartan on the macrophage infiltration and TGF- β 1 expression

The detection in the accumulation of CD68 positive cells in the myocardium by immunohistochemistry was represented as an indicator of macrophage infiltration. The results showed that in the AAC group, the large number of macrophages is recruited in the peri-vascular region and interstitial myocardium at week 16 (Figure 3A), which was attenuated by treatment with liraglutide or telmisartan. Consistent with enhanced macrophage infiltration in the AAC group, the expression of TGF- β 1 in the myocardium

Figure 3 Effects of liraglutide and telmisartan on the accumulation of macrophages and the expression TGF- β 1. **(A)** The numbers of macrophages were determined by positively stained cells (arrows) using immunohistochemistry. **(B)** TGF- β 1 expression in the intermyocardium was determined using immunohistochemistry and calculated as MOD in the tissue section (magnification: 200; scale bars: 100 μ m). **(C)** Protein level of TGF- β 1 was detected by Western blot assay. Values are mean $\pm$ SEM (n=6/group). * p <0.05 AAC vs Sham; # p <0.05 Lira or Telmi vs AAC.

Abbreviations: AAC, abdominal aortic constriction; MOD, mean optical density.

was also significantly increased (Figure 3B). The measurement of protein level of TGF- β 1 by Western blot assay further confirmed the change in the TGF- β 1 expression (Figure 3C). Administration of liraglutide or telmisartan during AAC comparatively reduced the infiltration of macrophages and expression of TGF- β 1 at week 16 compared with the AAC group (Figure 3).

Effects of liraglutide and telmisartan on the myofibroblast proliferation and Smad expression

The detection in the number of α -SMA positive cells in the myocardium was indicated as a parameter to reflect the fibroblast proliferation. As shown in Figure 4A, relative to the Sham control, the abundant α -SMA positive myofibroblasts were identified by immunohistochemical staining following 16 weeks of AAC, predominantly located in the outside of the blood vessels in the myocardium.

However, the appearance of α -SMA positive myofibroblasts at week 16 was inhibited by administration of liraglutide or telmisartan compared with the AAC group.

The disruption in the protein expression of Smad family members following TGF- β 1 signaling is associated with myofibroblast activation and collagen deposition. Smad2 and Smad3 were barely phosphorylated in the Sham control. However, at 16 weeks of AAC as analyzed by Western blot assay, the phosphorylation of Smad2/3 was markedly enhanced, consistent with increased total protein levels of Smad2/3 (Figure 4B). Furthermore, the total protein level of Smad4 was significantly upregulated (Figure 4C), and total protein expression of Smad7 was downregulated (Figure 4D) relative to the Sham group. However, all these changes in the protein expression of Smad family members induced by AAC were significantly reversed by administration of liraglutide or telmisartan (Figure 4B–D).

Figure 4 Effects of liraglutide and telmisartan on the proliferation of myofibroblasts and the expression of Smads. **(A)** The numbers of myofibroblasts were determined by α -SMA positive cells (arrows) using immunohistochemistry. **(B)** Phosphorylated and total protein levels of Smad2 and Smad3 were detected by Western blot assay. **(C and D)** Protein levels of Smad4 and Smad7 were detected by Western blot assay. Values are mean $\pm$ SEM (n=6/group). * p <0.05 AAC vs Sham; # p <0.05 Lira or Telmi vs AAC. **Abbreviation:** AAC, abdominal aortic constriction.

Effects of liraglutide and telmisartan on collagen synthesis and tissue fibrosis after AAC

Phosphorylation of Smads is responsible for induction of collagens. Along with enhanced phosphorylation of Smad2/3, the protein levels of collagens I and III examined by Western blot assay were significantly increased at 16 weeks of AAC compared with the Sham control (Figure 5A and B). Administration of liraglutide or telmisartan was equally effective in reducing the production of collagen I and III after the rats were treated with these drugs. Collagen deposition was evaluated using Masson's trichrome staining. Consistent with upregulated expression of collagens I and III at 16 weeks of AAC, the region of deposited collagens as defined by percent collagen-rich areas was significantly expanded in the perivascular and interstitial myocardium. No newly synthesized collagens were detected in the Sham control throughout the experiment. The hearts treated with liraglutide or telmisartan showed a significant reduction in collagen deposition in both perivascular region and intermyocardium as defined by reduced collagen-rich area (Figure 5C).

Effects of liraglutide and telmisartan on cardiac performance after AAC

Two-dimensional ultrasound system was used to detect the cardiac function after AAC and interventions. As shown in Figure 6A, AAC caused a significant increase in the LVIDd relative to the Sham group at 16 weeks of the experiment (Figure 6B), suggesting left ventricular enlargement (dilation and hypertrophy), consistent with increased cardiomyocyte hypertrophy (Figure 1C). Furthermore, cardiac systolic function as assessed by LVEF (Figure 6C) and LVFS (Figure 6D) was reduced by AAC relative to the Sham group. Treatment with liraglutide or telmisartan enhanced cardiac performance compared with results in AAC group (Figure 6). To confirm the echocardiography results, cardiac function was further analyzed by a BL-410 biological signal acquisition and processing system. At week 16, AAC significantly increased MAP, HR and LVEDP (Figure 7A), and reduced LVSP (Figure 7B) relative to the Sham control. Furthermore, the maximal rate in increase of LV pressure (+dp/dt_{max}) and decrease of LV pressure (-dp/dt_{max}) were significantly reduced (Figure 7B). Treatment with liraglutide and telmisartan for 16 weeks effectively prevented the progression of cardiac dysfunction (Figure 7), consistent with the inhibition of cardiac hypertrophy and fibrosis.

Figure 5 Effects of liraglutide and telmisartan on the synthesis of collagens and tissue fibrosis after AAC. **(A and B)** Protein levels of collagens I and III were analyzed by Western blot assay. All bands were normalized by actin as illustrated in the bar graphs. **(C)** Interstitial and perivascular fibrosis in the myocardium was identified as collagen deposition shown as positive areas of blue staining using Masson's trichrome method. All images were viewed under magnification 200 (scale bars: 100 μ m). Values are mean $\pm$ SEM (n=6/group). * p <0.05 AAC vs Sham; # p <0.05 Lira or Telmi vs AAC.

Abbreviation: AAC, abdominal aortic constriction.

Discussion

We have previously demonstrated that Ang II acts via its AT1R to increase blood pressure and cardiac fibrosis.^{12,13} In the present study, we evaluated the effect of exogenous administration of liraglutide on AAC-induced cardiac fibrosis and dysfunction, primarily focusing on the modulation on Ang II AT1R-mediated signaling. We found that treatment with liraglutide rebalances the pro- and anti-oxidative stress, including MDA, SOD, and NT-pro-BNP. Following the downregulation in AT1R expression and upregulation in the AT2R/ACE2 expression, the migration of macrophages and proliferation of myofibroblasts were inhibited, and TGF- β 1/Smads-mediated collagen deposition was attenuated. In association with an inhibition of myocardial hypertrophy and HW/BW ratio, cardiac performance was improved, suggesting that stimulation in GLP-1 receptor is

effective to reduce Ang II-mediated deleterious effects on the heart. Comparative protection with telmisartan confirmed that the cardioprotection by liraglutide is achieved through blocking the AT1R.¹²

Published data have suggested that the balance in the protein expression between AT1R and AT2R plays a fundamental role in the development of cardiac fibrosis and progression of cardiac dysfunction.^{22–25} Pharmacological blockade of the AT1R is associated with the improvement of cardiac function and the attenuation of hypertension.^{26,27} Based on the results shown in Figure 2, we found that there is a reciprocal relationship in the protein expression between the AT1R and the AT2R after AAC. Stimulation of the AT1R signaling perturbs the AT2R expression. We have previously shown that blockade of the AT1R after Ang II infusion is accompanied with an upregulation of the

Figure 6 Effects of liraglutide and telmisartan on cardiac performance after AAC. **(A)** Cardiac global function was quantitatively assessed from two-dimensional echocardiographic short axis images among the different groups. **(B)** Left ventricular internal diameter end diastole (LVIDd) was measured at end-diastole. **(C and D)** Cardiac systolic function was determined by measuring ejection fraction (EF) and fraction shortening (FS). Values are mean $\pm$ SEM (n=6/group). * p <0.05 AAC vs Sham; # p <0.05 Lira or Telmi vs AAC.

Abbreviation: AAC, abdominal aortic constriction.

AT2R, suggesting that the AT1R interacts with the AT2R.^{12,13} The data presented in the present study further confirmed this reciprocal expression relationship between the AT1R and AT2R. Furthermore, activation of Ang II AT1R by AAC resulted in excessive production of reactive oxygen species, manifested by a significant elevation of MDA content and reduction of SOD activity. Comparative modulation in MDA and SOD between liraglutide and telmisartan suggested that inhibition of oxidant production with liraglutide is potentially achieved by blocking the AT1R. Followed by the AT2R internalization along with AT1R antagonism by liraglutide, macrophage migration, myofibroblast proliferation, and collagen deposition were inhibited. However, it is warranted to further check whether direct blockade with the AT2R-specific inhibitor or using an AT2R knockout model could interfere the pressure overload-induced cardiac remodeling and dysfunction.

ACE2 is an exopeptidase that catalyzes the conversion of Ang II to Ang (1–7). An increase in ACE2 activity is

associated with a decrease in tissue level of Ang II.^{28–30} In contrast, loss of ACE2 leads to an increase in blood pressure, progressive ventricular dilatation, and poor systolic performance, which all are accompanied with an elevation in Ang II level in the heart.³¹ It is known from the literature that at protein level, the expression of the AT1R and ACE can be modified by the AT1R blockade.³² In this regard, we have previously reported that Ang II infusion-induced upregulation in AT1 receptor and reduction in ACE2 expression can be blocked by liraglutide and telmisartan.^{12,21} In the present study, AAC caused significant reduction in the expression of ACE2 that is also blocked by the AT1R blocker, further confirming an involvement of the AT1R in interfering ACE2 expression. Being consistent with downregulation of the AT1R with liraglutide,¹² ACE2 expression was enhanced, suggesting that this action may further enhance the inhibitory effects of the AT1R antagonism on AAC-induced cardiac remodeling and dysfunction. We

Figure 7 Effects of liraglutide and telmisartan on cardiac hemodynamics after AAC. **(A)** Representative tracing of the invasive cardiac hemodynamics recording among the different groups. MAP, HR, and left ventricular end-diastolic pressure (LVEDP) were obtained using a pressure transducer inserted into the left ventricle through the right carotid artery. **(B)** Left ventricular systolic pressure (LVSP) and $\pm dp/dt_{max}$ values of the first derivative of left ventricular pressure were obtained using a pressure transducer inserted into the left ventricle. Values are mean $\pm$ SEM ($n=6$ /group). * $p<0.05$ AAC vs Sham; # $p<0.05$ Lira or Telmi vs AAC.

Abbreviations: AAC, abdominal aortic constriction; HR, heart rate.

speculate that an alteration in the balance of AT1R and ACE2 by liraglutide might protect the heart against Ang II mediated adverse effects through the beneficial modulation in response to Ang (1–7) generation. However, in future studies, it is interesting to further evaluate the efficacy of cardioprotection between liraglutide and agonist of ACE2–Ang-(1–7) axis.

Ventricular remodeling often occurs as a consequence of chronic pressure overload, resulting in progressive alterations in size, mass, and structure of the heart. The process is associated with poor prognosis due to ventricular dysfunction.³³ Animal studies and clinical implications of cardiac remodeling have provided strong evidence showing that stimulation of Ang II, production of reactive oxygen species, release of inflammatory mediators, and deposition of collagen are mostly implicated in the development of cardiac remodeling.³⁴ In the present study, cardiac remodeling is chartered by cardiac myocyte

hypertrophy and tissue fibrosis. At 16 weeks of AAC, cardiomyocyte cross-sectional analysis by HE staining revealed a significant increase in cardiomyocyte size and Masson's trichrome staining confirmed an abundant perivascular and interstitial collagen deposition. In the cellular level, AAC caused a significant increase in oxidative stress, migration of macrophages, and proliferation of myofibroblasts. In the protein level, expression of TGF- β 1/Smads was upregulated and deposition of collagens was enhanced. However, these changes induced by AAC were significantly inhibited with 16 weeks of liraglutide treatment. Comparative protection between liraglutide and telmisartan confirmed the protection is mediated by modulating the AT1R. These results were consistent with our previous report showing that inhibition of TGF β 1 expression with an anti-oxidant compound suppresses fibroblast proliferation and interrupts phosphorylation of Smad2/3 to form a heterotrimeric complex with Smad4 whereas

Smad7, an inhibitor of phosphorylation of Smad2/3, is upregulated.¹³

Increased fibrosis of the ventricle can result in a failure to relax appropriately which impairs cardiac filling to lead to heart failure with reduced EF.^{35–37} We selected 16 weeks of experimental period for abdominal aortic stenosis because it can reflect the natural progression of cardiac dysfunction. We may miss a time window to reflect compensatory response, ie, concentric hypertrophy with normal EF in the early stage of AAC, but did find a reduction in EF following 16 weeks of period of chronic hemodynamic overload. Data clearly showed a significant ventricular dilatation and systolic dysfunction at this time point, as evidenced by increased HW/BW ratio, LVID, and MSA in series, suggesting the development of the eccentric hypertrophy. At the same time, LVEDP was increased, and LVSP, dp/dt_{max}, and EF were reduced, indicating that there is an increase in ventricular compliance and elevated filling pressure, often attributing to cardiac systolic dysfunction. Treatment with liraglutide for 16 weeks significantly reduced collagen deposition/fibrosis with less chamber dilatation and enhanced cardiac systolic function, suggesting that mechanisms of action underlying liraglutide protection under a condition of chronic pressure-overload are associated with an inhibition of tissue fibrosis.^{38–40} Although we cannot conclude whether liraglutide has a direct inotropic effect on the heart, the comparative inhibition in lipid peroxidation, hypertrophy, and fibrosis demonstrated between liraglutide and telmisartan in the present study suggest that these beneficial effects are primarily mediated by blockade of the AT1R.

Conclusion

In summary, we demonstrate that liraglutide protects the heart against the pressure overload with AAC induced cardiac injury in rat. The signaling pathways underlying inhibition of myocardial fibrosis and prevention of cardiac systolic dysfunction is primarily mediated by a downregulation of Ang II AT1R. Blockade of the AT1R with liraglutide, and also by application of telmisartan come along with upregulation of the AT2R and ACE2 as well as inhibition of the downstream fibrotic mediators (ie, TGFβ1 and Smad2/3). In line with these findings, cardiac hypertrophy and fibrosis were attenuated. Since cardiac fibrosis has been confirmed to be the final pathway leading to ventricular dysfunction and heart failure, liraglutide in addition to its effect on the blood glucose control might be

considered as a second-line add-on therapy to protect the heart against fibrosis-induced heart failure in patients.

Acknowledgment

This study was supported in part by grants from the Mercer University School of Medicine, the Medcen Community Health Foundation, Georgia, and the National Natural Science Foundation of China (81470436).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Tham YK, Bernardo BC, Ooi JY, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. *Arch Toxicol*. 2015;89(9):1401–1438. doi:10.1007/s00204-015-1477-x
2. Jackson JD, Cotton SE, Bruce Wirta S, et al. Burden of heart failure on patients from China: results from a cross-sectional survey. *Drug Des Devel Ther*. 2018;12:1659–1668. doi:10.2147/DDDT.S148949
3. Liehn EA, Postea O, Curaj A, Marx N. Repair after myocardial infarction between fantasy and reality. *J Am Coll Cardiol*. 2011;58(23):2357–2362. doi:10.1016/j.jacc.2011.08.034
4. Cohn JN, Ferrari R, Sharpe N; Behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. *J Am Coll Cardiol*. 2000;35(3):569–582. doi:10.1016/s0735-1097(99)00630-0
5. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. *Circulation*. 2007;115(12):1563–1570. doi:10.1161/CIRCULATIONAHA.106.666818
6. Wu QQ, Xiao Y, Yuan Y, et al. Mechanisms contributing to cardiac remodeling. *Clin Sci (Lond)*. 2017;131(18):2319–2345. doi:10.1042/CS20171167
7. Suthahar N, Meijers WC, Silljé HHW, de Boer RA. From inflammation to fibrosis-molecular and cellular mechanisms of myocardial tissue remodeling and perspectives on differential treatment opportunities. *Curr Heart Fail Rep*. 2017;14(4):235–250. doi:10.1007/s11897-017-0343-y
8. Bacmeister L, Schwarzl M, Warnke S, et al. Inflammation and fibrosis in murine models of heart failure. *Basic Res Cardiol*. 2019;114(3):19–54. doi:10.1007/s00395-019-0722-5
9. Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. *J Vet Intern Med*. 2019;33(2):363–382. doi:10.1111/jvim.15454
10. Côté N, Mahmut A, Fournier D, et al. Angiotensin receptor blockers are associated with reduced fibrosis and interleukin-6 expression in calcific aortic valve disease. *Pathobiology*. 2014;81(1):15–24. doi:10.1159/000350896
11. Müller P, Kazakov A, Semenov A, et al. Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs. *J Cardiovasc Pharmacol Ther*. 2013;18(1):87–93. doi:10.1177/1074248411434773
12. Zhang LH, Pang XF, Bai F, et al. Preservation of glucagon-like peptide-1 level attenuates angiotensin II-induced tissue fibrosis by altering AT1/AT2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart. *Cardiovasc Drugs Ther*. 2015;29(3):243–255. doi:10.1007/s10557-015-6592-7

13. Zhang WW, Bai F, Wang J, et al. Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor. *Drug Des Devel Ther.* 2017;11:3019–3033. doi:10.2147/DDDT.S144807
14. Crowley MJ, Powers BJ, Myers ER, McBroom AJ, Sanders G. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: future research needs prioritization. *Am Heart J.* 2012;163:777–782. doi:10.1016/j.ahj.2012.02.016
15. Ram CVS. Angiotensin receptor blockers: current status and future prospects. *Am J Med.* 2008;121:656–663. doi:10.1016/j.amjmed.2008.02.038
16. Pabreja K, Mohd MA, Kode C, Wootten D, Furness SGB. Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. *Br J Pharmacol.* 2014;171:1114–1128. doi:10.1111/bph.12313
17. Liu J, Liu Y, Chen L, et al. Glucagon-like peptide-1 analog liraglutide protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway. *J Diabetes Res.* 2013;2013(5):1–8.
18. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2016;375(4):311–322. doi:10.1056/NEJMoa1603827
19. Abdul-Ghani M, DeFronzo RA, Del Prato S, et al. Cardiovascular disease and type 2 diabetes: has the dawn of a new era arrived? *Diabetes Care.* 2017;40(7):813–820. doi:10.2337/dc16-2736
20. Svanström H, Ueda P, Melbye M, et al. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. *Lancet Diabetes Endocrinol.* 2019;7(2):106–114. doi:10.1016/S2213-8587(18)30320-6
21. Bai F, Pang XF, Zhang LH, et al. Angiotensin II AT1 receptor alters ACE2 activity, eNOS expression and CD44-hyaluronan interaction in rats with hypertension and myocardial fibrosis. *Life Sci.* 2016;153:141–152. doi:10.1016/j.lfs.2016.04.013
22. Meyers TA, Heitzman JA, Krebsbach AM, et al. Acute AT₁R blockade prevents isoproterenol-induced injury in mdx hearts. *J Mol Cell Cardiol.* 2019;128:51–61. doi:10.1016/j.yjmcc.2019.01.013
23. Jones ES, Black MJ, Widdop RE. Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. *J Mol Cell Cardiol.* 2004;37(5):1023–1030. doi:10.1016/j.yjmcc.2004.08.004
24. Namsolleck P, Recarti C, Foulquier S, Steckelings UM, Unger T. AT2 receptor and tissue injury: therapeutic implications. *Curr Hypertens Res.* 2014;16:416–426. doi:10.1007/s11906-013-0416-6
25. Oishi Y, Ozono R, Yoshizumi M, Akishita M, Horiuchi M, Oshima T. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. *Life Sci.* 2006;80(1):82–88. doi:10.1016/j.lfs.2006.08.033
26. Perret-Guillaume C, Joly L, Jankowski P, Benetos A. Benefits of the RAS blockade: clinical evidence before the ONTARGET study. *J Hypertens Suppl.* 2009;27(2):S3–S7. doi:10.1097/01.hjh.0000354511.14086.fl
27. Minas JN, Thorwald MA, Conte D, Vázquez-Medina JP, Nishiyama A, Ortiz RM. Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats. *Clin Exp Pharmacol Physiol.* 2015;42(11):1178–1188. doi:10.1111/1440-1681.12473
28. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: from angiotensin I to angiotensin (1–7). *Cardiovasc Res.* 2007;73(3):463–469. doi:10.1016/j.cardiores.2006.09.006
29. Wang W, McKinnie SM, Farhan M, et al. Angiotensin-converting enzyme 2 metabolizes and partially inactivates Pyr-Apelin-13 and Apelin-17: physiological effects in the cardiovascular system. *Hypertension.* 2016;68(2):365–377. doi:10.1161/HYPERTENSIONA.115.06892
30. Zhang W, Miao J, Wang S, Zhang Y. The protective effects of beta-casomorphin-7 against glucose-induced renal oxidative stress in vivo and vitro. *PLoS One.* 2013;8(5):e63472. doi:10.1371/journal.pone.0063472
31. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature.* 2002;417(6891):822–828. doi:10.1038/nature00786
32. Wang X, Ye Y, Gong H, et al. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1–7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. *J Mol Cell Cardiol.* 2016;97:180–190. doi:10.1016/j.yjmcc.2016.05.012
33. Fabiani I, Pugliese NR, La Carrubba S, et al. Incremental prognostic value of a complex left ventricular remodeling classification in asymptomatic for heart failure hypertensive patients. *J Am Soc Hypertens.* 2017;11(7):412–419. doi:10.1016/j.jash.2017.05.005
34. Forrester SJ, Booz GW, Sigmund CD, et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. *Physiol Rev.* 2018;98(3):1627–1738. doi:10.1152/physrev.00038.2017
35. Triposkiadis F, Giamouzis G, Boudoulas KD, et al. Left ventricular geometry as a major determinant of left ventricular ejection fraction: physiological considerations and clinical implications. *Eur J Heart Fail.* 2018;20(3):436–444. doi:10.1002/ehf.1055
36. Fabijanovic D, Milicic D, Cikes M. Left ventricular size and ejection fraction: are they still relevant? *Heart Fail Clin.* 2019;15(2):147–158. doi:10.1016/j.hfc.2018.12.012
37. Tomoaia R, Beyer RS, Simu G, Serban AM, Pop D. Understanding the role of echocardiography in remodeling after acute myocardial infarction and development of heart failure with preserved ejection fraction. *Med Ultrason.* 2019;21(1):69–76. doi:10.11152/mu-1768
38. Esposito G, Cappetta D, Russo R, et al. Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. *Br J Pharmacol.* 2017;174(22):4070–4086. doi:10.1111/bph.13686
39. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Circulation.* 2017;136(9):849–870. doi:10.1161/CIRCULATIONA.117.028136
40. Gaspari T, Brdar M, Lee HW, et al. Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis. *Diab Vasc Dis Res.* 2016;13(1):56–68. doi:10.1177/1479164115605000

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also

been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

Dovepress